https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/using-new-wearable-technology-monitor-niemann-pick-disease/
Using new wearable technology to monitor Niemann-Pick disease
22 Mar 2016, 4:15 p.m.
A smartphone app, combined with wearable technology, will allow doctors to remotely monitor patients with conditions that limit their ability to voluntarily move their muscles. The app, known as 'aparito', uses a motion-tracking writsband to record the movements of patients with ataxia, and other related ambulatory conditions.
The data from the tracker is sent via a smartphone app, where it can be combined with other information such as medication adherence and events such as falls or seizures. Healthcare professionals can have constant access to this information via the web.
Great Ormond Street BRC-researcher Professor Paul Gissen, has been working closely with aparito, and Great Ormond Street Hospital is to be the first in the UK to use this new wearable technology in clinical practice. Patients could receive fewer tests and have shorter hospital visits by using the app, which will monitor routine activity in a continuous, non-invasive way.
New treatment for brain tumour approved after over 20 years of research
The first-ever targeted treatment for brain tumours in children has been approved for NHS patients, following decades of research by a Great Ormond Street consultant.
Help pioneer new treatments for millions of people this DNA Day
DNA Day is coming up this Thursday (25 April) and the team behind the DNA, Children + Young People’s Health Resource (D-CYPHR) are encouraging children and young people to contribute to important health research.
New study finds that nasal cells protect against Covid-19 in children
New research shows that children are less likely than adults to develop severe COVID because cells in their nose are better at fighting off the virus.
New plan announced to get more children access to gene therapy treatments
Great Ormond Street Hospital (GOSH) has announced plans to revolutionise how children living with a rare disease can gain access to life-changing treatments.